Avadel Pharmaceuticals rises on quarterly revenue beat

Avadel Pharmaceuticals

03/03/2025 13:26

** Shares of drugmaker Avadel Pharmaceuticals AVDL.O up 3% at $8.15 premarket

** Co posts Q4 net product revenue of $50.4 million on sales of its muscle weakness drug, Lumryz; above analysts' average estimate of $50.03 million, according to data compiled by LSEG

** Co reiterates 2025 forecast net product revenue of $240 million to $260 million, compared with estimates of $251.17 million

** AVDL has fallen 40% in the last 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))